Monashee Investment Management LLC Acquires 160,862 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Monashee Investment Management LLC increased its stake in Structure Therapeutics Inc. by 121.9% during the first quarter, owning a total of 292,862 shares valued at approximately $5 million.
• Institutional investors and hedge funds hold 91.78% of the stock, indicating strong institutional interest in Structure Therapeutics.
• Analysts have a consensus Buy rating on the stock with an average target price of $75.71, reflecting anticipated growth potential.

Monashee Investment Management LLC raised its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 121.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 292,862 shares of the company's stock after buying an additional 160,862 shares during the quarter. Structure Therapeutics comprises about 0.6% of Monashee Investment Management LLC's portfolio, making the stock its 25th largest position. Monashee Investment Management LLC owned about 0.51% of Structure Therapeutics worth $5,069,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of GPCR. LPL Financial LLC increased its holdings in Structure Therapeutics by 6.0% in the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company's stock valued at $311,000 after buying an additional 646 shares during the period. Geode Capital Management LLC boosted its stake in shares of Structure Therapeutics by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 45,705 shares of the company's stock valued at $1,240,000 after purchasing an additional 480 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Structure Therapeutics by 202.5% in the 4th quarter. Wells Fargo & Company MN now owns 10,103 shares of the company's stock valued at $274,000 after purchasing an additional 6,763 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Structure Therapeutics by 12.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock valued at $201,000 after purchasing an additional 843 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Structure Therapeutics by 4.1% in the 4th quarter. Invesco Ltd. now owns 371,767 shares of the company's stock valued at $10,082,000 after purchasing an additional 14,559 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on GPCR shares. Guggenheim cut their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. Citigroup started coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They set a "buy" rating and a $60.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, June 23rd. HC Wainwright cut their target price on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. Finally, JMP Securities cut their target price on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 7th. Eight research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Structure Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $75.71.

Structure Therapeutics Stock Down 0.1%

Structure Therapeutics stock traded down $0.03 during mid-day trading on Tuesday, hitting $18.55. 128,648 shares of the stock were exchanged, compared to its average volume of 864,338. The firm's fifty day simple moving average is $19.20 and its two-hundred day simple moving average is $20.97. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -17.68 and a beta of -1.89. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $13.22 and a 12 month high of $45.37.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.08). As a group, analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.